CN107158130B - Chinese patent medicine for treating hypertension - Google Patents
Chinese patent medicine for treating hypertension Download PDFInfo
- Publication number
- CN107158130B CN107158130B CN201710336312.3A CN201710336312A CN107158130B CN 107158130 B CN107158130 B CN 107158130B CN 201710336312 A CN201710336312 A CN 201710336312A CN 107158130 B CN107158130 B CN 107158130B
- Authority
- CN
- China
- Prior art keywords
- parts
- carrots
- putting
- temperature
- taking out
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000003814 drug Substances 0.000 title claims abstract description 51
- 206010020772 Hypertension Diseases 0.000 title claims abstract description 40
- 239000000843 powder Substances 0.000 claims abstract description 23
- 229940079593 drug Drugs 0.000 claims abstract description 6
- 239000002994 raw material Substances 0.000 claims abstract description 6
- 244000000626 Daucus carota Species 0.000 claims description 49
- 235000002767 Daucus carota Nutrition 0.000 claims description 49
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 17
- 235000013399 edible fruits Nutrition 0.000 claims description 12
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 9
- 241000207783 Ipomoea Species 0.000 claims description 9
- 238000003756 stirring Methods 0.000 claims description 9
- 238000009835 boiling Methods 0.000 claims description 8
- 241001113925 Buddleja Species 0.000 claims description 7
- 241000830535 Ligustrum lucidum Species 0.000 claims description 7
- 235000004347 Perilla Nutrition 0.000 claims description 7
- 244000124853 Perilla frutescens Species 0.000 claims description 7
- 240000004064 Poterium sanguisorba Species 0.000 claims description 7
- 235000008291 Poterium sanguisorba Nutrition 0.000 claims description 7
- 235000010426 Sambucus chinensis Nutrition 0.000 claims description 7
- 235000008282 Sanguisorba officinalis Nutrition 0.000 claims description 7
- 240000006079 Schisandra chinensis Species 0.000 claims description 7
- 238000000227 grinding Methods 0.000 claims description 7
- 239000007788 liquid Substances 0.000 claims description 6
- 238000003860 storage Methods 0.000 claims description 6
- 238000010009 beating Methods 0.000 claims description 5
- 238000005520 cutting process Methods 0.000 claims description 5
- 238000001035 drying Methods 0.000 claims description 5
- 238000007710 freezing Methods 0.000 claims description 5
- 230000008014 freezing Effects 0.000 claims description 5
- 238000002360 preparation method Methods 0.000 claims description 5
- 238000009777 vacuum freeze-drying Methods 0.000 claims description 5
- 238000005406 washing Methods 0.000 claims description 5
- 241000045403 Astragalus propinquus Species 0.000 claims description 4
- 240000006322 Sambucus chinensis Species 0.000 claims description 4
- 235000006533 astragalus Nutrition 0.000 claims description 4
- 238000000034 method Methods 0.000 claims description 4
- 238000002156 mixing Methods 0.000 claims description 3
- 239000002245 particle Substances 0.000 claims description 3
- 239000002002 slurry Substances 0.000 claims description 3
- 235000008422 Schisandra chinensis Nutrition 0.000 claims description 2
- 239000011361 granulated particle Substances 0.000 claims 1
- 210000004369 blood Anatomy 0.000 abstract description 13
- 239000008280 blood Substances 0.000 abstract description 13
- 230000000694 effects Effects 0.000 abstract description 8
- 150000002500 ions Chemical class 0.000 abstract description 8
- 210000004351 coronary vessel Anatomy 0.000 abstract description 6
- UCTWMZQNUQWSLP-UHFFFAOYSA-N adrenaline Chemical compound CNCC(O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-UHFFFAOYSA-N 0.000 abstract description 4
- 206010003119 arrhythmia Diseases 0.000 abstract description 4
- 230000006793 arrhythmia Effects 0.000 abstract description 4
- 241000628997 Flos Species 0.000 abstract description 3
- 210000000582 semen Anatomy 0.000 abstract description 3
- 102000003914 Cholinesterases Human genes 0.000 abstract description 2
- 108090000322 Cholinesterases Proteins 0.000 abstract description 2
- 239000009636 Huang Qi Substances 0.000 abstract description 2
- 230000017531 blood circulation Effects 0.000 abstract description 2
- 230000036772 blood pressure Effects 0.000 abstract description 2
- 229940048961 cholinesterase Drugs 0.000 abstract description 2
- 208000029078 coronary artery disease Diseases 0.000 abstract description 2
- 206010012601 diabetes mellitus Diseases 0.000 abstract description 2
- 210000005036 nerve Anatomy 0.000 abstract description 2
- 210000005259 peripheral blood Anatomy 0.000 abstract description 2
- 239000011886 peripheral blood Substances 0.000 abstract description 2
- 230000011514 reflex Effects 0.000 abstract description 2
- 230000002889 sympathetic effect Effects 0.000 abstract description 2
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 abstract 1
- 229960004373 acetylcholine Drugs 0.000 abstract 1
- 230000001457 vasomotor Effects 0.000 abstract 1
- 241000699670 Mus sp. Species 0.000 description 23
- 241000699666 Mus <mouse, genus> Species 0.000 description 12
- 241001465754 Metazoa Species 0.000 description 8
- 210000000056 organ Anatomy 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 6
- 238000011888 autopsy Methods 0.000 description 4
- 210000003743 erythrocyte Anatomy 0.000 description 4
- 239000008187 granular material Substances 0.000 description 4
- 230000001575 pathological effect Effects 0.000 description 4
- 238000010298 pulverizing process Methods 0.000 description 4
- 230000009897 systematic effect Effects 0.000 description 4
- MFYSUUPKMDJYPF-UHFFFAOYSA-N 2-[(4-methyl-2-nitrophenyl)diazenyl]-3-oxo-n-phenylbutanamide Chemical compound C=1C=CC=CC=1NC(=O)C(C(=O)C)N=NC1=CC=C(C)C=C1[N+]([O-])=O MFYSUUPKMDJYPF-UHFFFAOYSA-N 0.000 description 3
- 241001254604 Angelica pubescens Species 0.000 description 3
- 241000219784 Sophora Species 0.000 description 3
- 229940107666 astragalus root Drugs 0.000 description 3
- 210000000170 cell membrane Anatomy 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 238000010562 histological examination Methods 0.000 description 3
- 241000123846 Buddleja officinalis Species 0.000 description 2
- 206010010774 Constipation Diseases 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 231100000403 acute toxicity Toxicity 0.000 description 2
- 230000007059 acute toxicity Effects 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 238000009395 breeding Methods 0.000 description 2
- 230000001488 breeding effect Effects 0.000 description 2
- 239000003651 drinking water Substances 0.000 description 2
- 235000020188 drinking water Nutrition 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 230000037406 food intake Effects 0.000 description 2
- 235000012631 food intake Nutrition 0.000 description 2
- 238000005469 granulation Methods 0.000 description 2
- 230000003179 granulation Effects 0.000 description 2
- 210000002216 heart Anatomy 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 230000000007 visual effect Effects 0.000 description 2
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 206010007191 Capillary fragility Diseases 0.000 description 1
- 206010017367 Frequent bowel movements Diseases 0.000 description 1
- 238000012449 Kunming mouse Methods 0.000 description 1
- 230000003504 ach effect Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 231100000460 acute oral toxicity Toxicity 0.000 description 1
- 238000011047 acute toxicity test Methods 0.000 description 1
- 210000004100 adrenal gland Anatomy 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000004872 arterial blood pressure Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 210000000918 epididymis Anatomy 0.000 description 1
- 201000010063 epididymitis Diseases 0.000 description 1
- 210000003238 esophagus Anatomy 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 231100000636 lethal dose Toxicity 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000006996 mental state Effects 0.000 description 1
- WSFSSNUMVMOOMR-NJFSPNSNSA-N methanone Chemical compound O=[14CH2] WSFSSNUMVMOOMR-NJFSPNSNSA-N 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 238000009401 outcrossing Methods 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 210000003079 salivary gland Anatomy 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 210000000278 spinal cord Anatomy 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- 210000001541 thymus gland Anatomy 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 210000003437 trachea Anatomy 0.000 description 1
- 210000003932 urinary bladder Anatomy 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/232—Angelica
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/35—Caprifoliaceae (Honeysuckle family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/39—Convolvulaceae (Morning-glory family), e.g. bindweed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/481—Astragalus (milkvetch)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/489—Sophora, e.g. necklacepod or mamani
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/535—Perilla (beefsteak plant)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/56—Loganiaceae (Logania family), e.g. trumpetflower or pinkroot
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/57—Magnoliaceae (Magnolia family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/63—Oleaceae (Olive family), e.g. jasmine, lilac or ash tree
- A61K36/638—Ligustrum, e.g. Chinese privet
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
- A61K36/739—Sanguisorba (burnet)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/79—Schisandraceae (Schisandra family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation, decoction
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention belongs to the technical field of Chinese patent medicines, and particularly relates to a Chinese patent medicine for treating hypertension, which is prepared from the following raw materials: radix Angelicae Pubescentis, radix Sangusorbae, herba Sambuci Chiensis, semen Pharbitidis, fructus Ligustri Lucidi, fructus Schisandrae chinensis, radix Sophorae Flavescentis, radix astragali, fresh flos Buddlejae, fresh folium Perillae, and radix Dauci Sativae powder; the invention can not only enhance the action of acetylcholine and adrenaline by cholinesterase resistance, inhibit the pressure-boosting reflex, inhibit the vasomotor center, block sympathetic nerves, expand peripheral blood vessels, reduce resistance, increase the resistance of capillary vessels, reduce the fragility of the capillary vessels, reduce blood fat, expand coronary arteries, increase the blood flow of the coronary arteries, prevent Ca2+The internal flow increases the concentration of negative ions in blood, thereby achieving the effect of reducing blood pressure, expanding coronary artery, resisting arrhythmia and reducing blood sugar, and having important significance for treating hypertension patients complicated with coronary heart disease, arrhythmia and diabetes.
Description
Technical Field
The invention belongs to the technical field of Chinese patent medicines, and particularly relates to a Chinese patent medicine for treating hypertension.
Background
The hypertension is characterized in that the arterial pressure is increased, the lack of negative ions in blood is an important reason for causing the hypertension, normal red blood cells, colloidal particles and the like in the blood are negatively charged and mutually repel each other to keep a certain distance, the red blood cells aged due to pathological changes are positively charged because electrons are strived for, the red blood cells are agglomerated due to the attraction of positive and negative ions, the negative ions can effectively repair the aged cell membrane potential to cause the aged cell membrane potential to become normal negatively charged cells, the negative ions repel each other to effectively reduce the blood viscosity and slow down the blood sedimentation, meanwhile, the negative ions can enhance the negative polarity trend of the colloidal particles in the blood to increase the colloidal stability of plasma proteins and keep the normal healthy state of the blood, therefore, if the content of the negative ions in the blood is insufficient, the cell membrane potential of the aged red blood cells can not be repaired, and the hypertension is caused, systemic diseases accompanied by functional or organic changes in organs such as heart, blood vessels, brain and kidney; therefore, the invention of the Chinese patent medicine capable of effectively treating hypertension has important significance on human health.
Disclosure of Invention
In order to solve the problems, the invention aims to provide a Chinese patent medicine for treating hypertension.
The invention is realized by the following technical scheme:
a Chinese patent medicine for treating hypertension is prepared from the following raw materials in parts by weight: 12.5-13 parts of radix angelicae pubescentis, 8.8-9.2 parts of garden burnet, 7.4-7.6 parts of sambucus chinensis, 1.3-1.4 parts of pharbitis seed, 2.2-2.4 parts of glossy privet fruit, 5.5-5.7 parts of schisandra chinensis, 3.3-3.5 parts of radix sophorae flavescentis, 9.7-9.9 parts of astragalus membranaceus, 17-18 parts of fresh butterflybush flower, 20-21 parts of fresh perilla leaf and 18-19 parts of carrot powder;
the carrot powder is prepared by the following steps: washing 25-26 parts by weight of carrots, cutting the carrots into blocks, putting the carrots into a grinder at the rotating speed of 3100-3300 r/min, grinding the carrots for 18-20 min, taking out the carrots, putting the carrots into 31-32 parts by weight of water, boiling the carrots with strong fire, decocting the carrots with slow fire for 26-28 min, continuously stirring the carrots with a stirrer at the rotating speed of 130-140 r/min, taking out the carrots, putting the carrots into a baking box at the temperature of 69-70 ℃, baking the carrots for 750-760 s at a constant temperature, taking out the carrots, putting the carrots into a vacuum freeze drying box at the temperature of-14 to-13 ℃, and drying the carrots until the.
As a further scheme of the invention: a preparation method of a Chinese patent medicine for treating hypertension specifically comprises the following steps:
(1) putting radix angelicae pubescentis, garden burnet, sambucus chinensis, radix sophorae flavescentis and astragalus mongholicus into a grinder with the rotating speed of 3800-4000 r/min, grinding for 43-45 min, taking out, putting into water with the weight being 19-20 times of that of the radix angelicae pubescentis, boiling with strong fire, decocting with slow fire for 55-57 min, taking out, and homogenizing for 24-26 min under the conditions that the temperature is 62-63 ℃ and the rotating speed is 170-180 r/min to obtain a middle liquid medicine;
(2) putting pharbitis seed, glossy privet fruit and Chinese magnoliavine fruit into a rotary frying pan at 74-75 ℃ for constant-temperature frying for 690-700 s, taking out, putting into a grinder at 860-880 r/min for grinding for 20-22 min, taking out, adding an acetic acid solution with the weight being 2.2-2.3 times of that of pharbitis seed and the mass fraction being 15% -16%, mixing and stirring uniformly, putting into the rotary frying pan at 60-61 ℃ for constant-temperature frying for 540-550 s, and taking out to obtain Chinese medicinal powder;
(3) putting fresh butterflybush flower and fresh perilla leaf into a beating machine with the rotating speed of 2700-2900 r/min, adding water with the weight being 1.7-1.8 times of the weight of the fresh butterflybush flower and the temperature of 56-57 ℃, beating for 34-36 min, taking out, putting into a freezing box with the temperature of-3 to-2 ℃, freezing for 670-680 s, taking out, putting into a baking box with the temperature of 86-87 ℃, baking for 850-860 s at constant temperature, and taking out to obtain traditional Chinese medicine slurry;
(4) the Chinese medicine liquid, the Chinese medicine powder, the Chinese medicine pulp and the carrot powder are put into a stirrer with the rotating speed of 570-590 r/min and stirred for 16-18 min, taken out, put into a cold storage box with the temperature of 3-4 ℃ for constant-temperature cold storage for 22-23 h, taken out, put into a baking box with the temperature of 88-89 ℃ for constant-temperature baking for 270-280 s, taken out, granulated, and adjusted to have the water content of 7.7% -7.9%, so that the Chinese patent medicine for treating hypertension is obtained.
As a further scheme of the invention: the grain size of the granules prepared in the step (4) is 2.4-2.5 mm.
The invention has the beneficial effects that: the Chinese patent medicine for treating hypertension provided by the invention can enhance acetylcholine effect through cholinesterase resistance, resist adrenaline, inhibit pressure-rising reflex, inhibit blood vessel movement center, block sympathetic nerve, expand peripheral blood vessel, reduce resistance, increase capillary resistance, reduce capillary fragility, reduce blood fat, expand coronary artery, increase coronary artery blood flow, prevent Ca2+The internal flow increases the concentration of negative ions in blood, thereby achieving the effect of reducing blood pressure, expanding coronary artery, resisting arrhythmia and reducing blood sugar, and having important significance for treating hypertension patients complicated with coronary heart disease, arrhythmia and diabetes.
Detailed Description
The invention is illustrated by the following specific examples, which are not intended to be limiting.
Example 1
In the embodiment of the invention, a Chinese patent medicine for treating hypertension is prepared from the following raw materials in parts by weight: 12.5 parts of pubescent angelica root, 8.8 parts of garden burnet root, 7.4 parts of Chinese elder herb, 1.3 parts of pharbitis seed, 2.2 parts of glossy privet fruit, 5.5 parts of Chinese magnoliavine fruit, 3.3 parts of lightyellow sophora root, 9.7 parts of astragalus root, 17 parts of fresh butterflybush flower, 20 parts of fresh perilla leaf and 18 parts of carrot powder;
the carrot powder is prepared by the following steps: washing 25 parts by weight of carrot, cutting into blocks, putting into a pulverizer at the rotation speed of 3100r/min, pulverizing for 18min, taking out, putting into 31 parts by weight of water, boiling with strong fire, decocting with slow fire for 26min, continuously stirring with a stirrer at the rotation speed of 130r/min, taking out, putting into a baking oven at the temperature of 69 ℃, baking for 750s at constant temperature, taking out, putting into a vacuum freeze drying oven at the temperature of-14 ℃, and drying until the water content is 8.2% to obtain the carrot powder.
As a further scheme of the invention: a preparation method of a Chinese patent medicine for treating hypertension specifically comprises the following steps:
(1) putting radix Angelicae Pubescentis, radix Sangusorbae, herba Sambuci Chiensis, radix Sophorae Flavescentis and radix astragali into a pulverizer at a rotation speed of 3800r/min, pulverizing for 43min, taking out, putting into water 19 times the weight of radix Angelicae Pubescentis, boiling with strong fire, decocting with slow fire for 55min, taking out, and homogenizing at 62 deg.C and a rotation speed of 170r/min for 24min to obtain Chinese medicinal liquid;
(2) putting semen Pharbitidis, fructus Ligustri Lucidi and fructus Schisandrae chinensis into a rotary frying pan at 74 deg.C, parching for 690s at constant temperature, taking out, grinding in a grinder at 860r/min for 20min, taking out, adding 15% acetic acid solution 2.2 times the weight of semen Pharbitidis, mixing, stirring, putting into a rotary frying pan at 60 deg.C, parching for 540s at constant temperature, and taking out to obtain Chinese medicinal powder;
(3) putting fresh flos Buddlejae and fresh folium Perillae into a beater with rotation speed of 2700r/min, adding water with weight of 1.7 times of fresh flos Buddlejae and temperature of 56 deg.C, beating for 34min, taking out, freezing in a freezer with temperature of-3 deg.C for 670s, taking out, baking in a baking oven with temperature of 86 deg.C for 850s, and taking out to obtain Chinese medicinal slurry;
(4) putting the traditional Chinese medicine liquid, the traditional Chinese medicine powder, the traditional Chinese medicine pulp and the carrot powder into a stirrer with the rotating speed of 570r/min, stirring for 16min, taking out, putting into a cold storage box with the temperature of 3 ℃ for cold storage for 22h at constant temperature, taking out, putting into a baking box with the temperature of 88 ℃ for baking for 270s at constant temperature, taking out, granulating, and adjusting the water content to 7.7% to obtain the Chinese patent medicine for treating hypertension.
As a further scheme of the invention: the grain diameter of the granulation in the step (4) is 2.4 mm.
Example 2
In the embodiment of the invention, a Chinese patent medicine for treating hypertension is prepared from the following raw materials in parts by weight: 12.8 parts of pubescent angelica root, 9 parts of garden burnet root, 7.5 parts of Chinese elder herb, 1.35 parts of pharbitis seed, 2.3 parts of glossy privet fruit, 5.6 parts of Chinese magnoliavine fruit, 3.4 parts of lightyellow sophora root, 9.8 parts of astragalus root, 17.5 parts of fresh buddleja officinalis, 20.5 parts of fresh perilla leaf and 18.5 parts of carrot powder;
the carrot powder is prepared by the following steps: washing 25.5 weight parts of carrot, cutting into pieces, putting into a pulverizer at the rotation speed of 3200r/min, pulverizing for 19min, taking out, putting into 31.5 weight parts of water, boiling with strong fire, decocting with slow fire for 27min, stirring with a stirrer at the rotation speed of 135r/min, taking out, putting into a baking oven at the temperature of 69.5 ℃, baking at constant temperature for 755s, taking out, putting into a vacuum freeze drying oven at the temperature of-13.5 ℃, and drying until the moisture content is 8.3% to obtain carrot powder.
As a further scheme of the invention: the preparation method of a Chinese patent medicine for treating hypertension is the same as that in example 1.
As a further scheme of the invention: the grain diameter of the granules in the step (4) is 2.45 mm.
Example 3
In the embodiment of the invention, a Chinese patent medicine for treating hypertension is prepared from the following raw materials in parts by weight: 13 parts of pubescent angelica root, 9.2 parts of garden burnet root, 7.6 parts of Chinese elder herb, 1.4 parts of pharbitis seed, 2.4 parts of glossy privet fruit, 5.7 parts of Chinese magnoliavine fruit, 3.5 parts of lightyellow sophora root, 9.9 parts of astragalus root, 18 parts of fresh buddleja officinalis, 21 parts of fresh perilla leaf and 19 parts of carrot powder;
the carrot powder is prepared by the following steps: washing 26 parts by weight of carrot, cutting into blocks, putting into a pulverizer at the rotating speed of 3300r/min, pulverizing for 20min, taking out, putting into 32 parts by weight of water, boiling with strong fire, decocting with slow fire for 28min, continuously stirring with a stirrer at the rotating speed of 140r/min, taking out, putting into a baking oven at the temperature of 70 ℃, baking for 760s at constant temperature, taking out, putting into a vacuum freeze drying oven at the temperature of-13 ℃, and drying until the water content is 8.4% to obtain the carrot powder.
As a further scheme of the invention: the preparation method of a Chinese patent medicine for treating hypertension is the same as that in example 1.
As a further scheme of the invention: the grain diameter of the granulation in the step (4) is 2.5 mm.
1. Purpose of the experiment: the mouse acute toxicity of the Chinese patent medicine for treating hypertension is observed
2. Animal(s) production
2.1. The source is as follows: the method comprises the steps of (1) carrying out outcrossing and sealing on SPF-level Kunming mice provided by an experimental animal experiment center of Anhui province;
2.2 weight: 23-25 g;
2.3 sex: half of a female and a half of a male;
2.4 animal numbers: 50, 5 breeding animals in each cage;
2.5 Experimental Environment: the laboratory temperature is 22-26 ℃, the relative humidity is 45-70%, and the light and the shade alternate day and night;
2.6 pellet feed: supplied by Nanjing Anriemer technologies, Inc.;
2.7 padding: supplied by Nanjing Anriemer technologies, Inc.;
2.8 drinking water: sterile water is drunk, and the source is Anhui province of medicine research institute.
3. Experimental methods
3.1 mouse LD50 Pre-test
Randomly taking 10 mice, each half of the mice is bred in a cage, after 12 hours of fasting (free drinking), 100 Chinese patent medicines for treating hypertension are given to each mouse ig, if the mice ig are given for the first time and do not die, the mice ig are given 3 times within 24 hours, and the breeding observation lasts for 3 days.
3.2 maximum dose test in mice
40 mice are taken and randomly divided into 2 groups, male and female are half, after fasting (free drinking water) for 12h, 100 Chinese patent medicines for treating hypertension are given to each mouse ig in an administration group, administration is repeated for 3 times in 24h in an equal amount, physiological saline in an equal amount is given to a control group, continuous feeding and observation are carried out for 13 days, toxic reaction conditions of the mice are observed every day, the weight and the feed consumption of the mice are weighed on 1 day before administration, the administration day, 1 day after administration, 3 days after administration, 5 days after administration, 7 days after administration, 9 days after administration, 11 days after administration and 13 days after administration, and the mice are killed on 14 days after administration.
3.2.1 systematic autopsy and histopathological examination
(1) And (3) carrying out systematic autopsy: roughly dissecting all experimental mice at the end of the experimental observation period, and roughly dissecting the animals killed by dying and dead animals in time in the experimental process and carrying out pathological and histological examination;
(2) pathological histological examination: the following organs of all experimental mice were subjected to histopathological examination: brain, heart, liver, pancreas, spleen, lung, trachea, salivary gland, thymus, kidney, adrenal gland, esophagus, stomach, small intestine, prostate, testis, epididymis, ovary, uterus, breast, bladder, spinal cord, and sternal bone marrow, each organ sample was fixed with 10% formaldehyde, sectioned by conventional paraffin embedding, HE stained, and examined by light microscope and photographed.
4. Results of the experiment
4.1 mouse LD50 mice were pretested to have 100 pills of the Chinese patent medicine for hypertension treatment of this example given 3 times, and no death of the mice was observed, suggesting that the mice could not make half of the lethal dose when the Chinese patent medicine for hypertension treatment of this example was given 3 times a day.
4.2 maximum dose test in mice
4.2.1 animal toxicity response: the mouse in the administration group has relatively reduced activity after each administration, poor spirit, reduced diet, increased stool frequency, recovery after 5-6 hours, slight hair pollution, no obvious difference in other indexes compared with a control group, normal recovery of all indexes after 24 hours of administration, and no obvious change in the aspects of behavior activity, mental state and the like of the mouse in 13 days of continuous observation compared with the control group.
4.2.2 weight Change before and after administration mice were fasted for 12h before administration, and since the dose on the day of administration greatly affected the animal feeding, the weight of mice in the control group and the administration group on the day of administration were reduced, but there was no statistical difference, and the weight did not change significantly in the rest period, and compared with the control group, the weight of the administration group was not significantly different, as detailed in Table 1:
TABLE 1 mouse weight conditions (g) before and after dosing
4.2.3 feed consumption before and after administration the day of animal feeding 12 hours before was fasting time, and compared with the control group, the food intake of the mice in the administration group on the 1 st day after administration was reduced but no significant difference, the main reason may be that the administration amount is large and affects the mice feeding, and the food intake of the mice in the other days is not abnormal, compared with the control group, the mice in the administration group have no significant difference, and the details are shown in table 2:
TABLE 2 average feed consumption (g) per mouse before and after dosing
4.2.4 mortality: after the administration, the mice were observed for 13 consecutive days without death.
4.2.5 systematic autopsy and histopathological examination
(1) And (3) carrying out systematic autopsy: roughly dissecting all experimental mice at the end of the experimental observation period, and carrying out comprehensive visual observation on each organ, wherein each organ is not abnormal in visual observation;
(2) pathological histological examination: pathological histology examination was performed on each organ mentioned in the examination items, and the results under an optical microscope showed that no significant lesions were observed in the organs of the control group and the high-dose group.
5. Conclusion of the experiment
The oral acute toxicity test of the Chinese patent medicine for treating the constipation by the invention is not tested to be LD50, so that the maximum administration experiment of the mouse ig is carried out, the maximum administration experiment result shows that the observed indexes have no obvious difference compared with the control group, and the death of the mouse is not seen, which shows that the acute toxicity of the Chinese patent medicine for treating the constipation is lower, the maximum administration amount of the mouse orally taken by the Chinese patent medicine for treating the hypertension per day is 300 granules, which is equivalent to 100 times of the clinically planned administration amount, and obviously, the Chinese patent medicine for treating the hypertension has certain safety in clinical acute administration.
The effect of the Chinese patent medicine for treating hypertension of the embodiment is as follows:
the method has the following advantages: reduction or disappearance of symptoms of discomfort; and (4) invalidation: the symptoms of discomfort are unchanged or worse.
60 patients with hypertension are randomly selected and divided into 3 groups, each group comprises 20 patients, each patient eats the Chinese patent medicine for treating hypertension for 3 times and 1 granule each time in a test period, the test time is 20 days, and the effect of the Chinese patent medicine for treating hypertension in the embodiment is shown in table 3:
TABLE 3 effects of the Chinese patent medicine for treating hypertension of the examples
As can be seen from table 3, the Chinese patent medicines for treating hypertension of the examples have significant effects of treating hypertension.
Claims (2)
1. The Chinese patent medicine for treating hypertension is characterized by being prepared from the following raw materials in parts by weight: 12.5-13 parts of radix angelicae pubescentis, 8.8-9.2 parts of garden burnet, 7.4-7.6 parts of sambucus chinensis, 1.3-1.4 parts of pharbitis seed, 2.2-2.4 parts of glossy privet fruit, 5.5-5.7 parts of schisandra chinensis, 3.3-3.5 parts of radix sophorae flavescentis, 9.7-9.9 parts of astragalus membranaceus, 17-18 parts of fresh butterflybush flower, 20-21 parts of fresh perilla leaf and 18-19 parts of carrot powder;
the carrot powder is prepared by the following steps: washing 25-26 parts by weight of carrots, cutting the carrots into blocks, putting the carrots into a grinder at the rotating speed of 3100-3300 r/min, grinding the carrots for 18-20 min, taking out the carrots, putting the carrots into 31-32 parts by weight of water, boiling the carrots with strong fire, decocting the carrots with slow fire for 26-28 min, continuously stirring the carrots with a stirrer at the rotating speed of 130-140 r/min, taking out the carrots, putting the carrots into a baking box at the temperature of 69-70 ℃, baking the carrots for 750-760 s at a constant temperature, taking out the carrots, putting the carrots into a vacuum freeze drying box at the temperature of-14 to-13 ℃, and drying the carrots until the;
the preparation method of the Chinese patent medicine for treating hypertension specifically comprises the following steps:
(1) putting radix angelicae pubescentis, garden burnet, sambucus chinensis, radix sophorae flavescentis and astragalus mongholicus into a grinder with the rotating speed of 3800-4000 r/min, grinding for 43-45 min, taking out, putting into water with the weight being 19-20 times of that of the radix angelicae pubescentis, boiling with strong fire, decocting with slow fire for 55-57 min, taking out, and homogenizing for 24-26 min under the conditions that the temperature is 62-63 ℃ and the rotating speed is 170-180 r/min to obtain a middle liquid medicine;
(2) putting pharbitis seed, glossy privet fruit and Chinese magnoliavine fruit into a rotary frying pan at 74-75 ℃ for constant-temperature frying for 690-700 s, taking out, putting into a grinder at 860-880 r/min for grinding for 20-22 min, taking out, adding an acetic acid solution with the weight being 2.2-2.3 times of that of pharbitis seed and the mass fraction being 15% -16%, mixing and stirring uniformly, putting into the rotary frying pan at 60-61 ℃ for constant-temperature frying for 540-550 s, and taking out to obtain Chinese medicinal powder;
(3) putting fresh butterflybush flower and fresh perilla leaf into a beating machine with the rotating speed of 2700-2900 r/min, adding water with the weight being 1.7-1.8 times of the weight of the fresh butterflybush flower and the temperature of 56-57 ℃, beating for 34-36 min, taking out, putting into a freezing box with the temperature of-3 to-2 ℃, freezing for 670-680 s, taking out, putting into a baking box with the temperature of 86-87 ℃, baking for 850-860 s at constant temperature, and taking out to obtain traditional Chinese medicine slurry;
(4) the Chinese medicine liquid, the Chinese medicine powder, the Chinese medicine pulp and the carrot powder are put into a stirrer with the rotating speed of 570-590 r/min and stirred for 16-18 min, taken out, put into a cold storage box with the temperature of 3-4 ℃ for constant-temperature cold storage for 22-23 h, taken out, put into a baking box with the temperature of 88-89 ℃ for constant-temperature baking for 270-280 s, taken out, granulated, and adjusted to have the water content of 7.7% -7.9%, so that the Chinese patent medicine for treating hypertension is obtained.
2. The method for preparing a Chinese patent drug for treating hypertension according to claim 1, wherein the granulated particles of step (4) have a particle size of 2.4 to 2.5 mm.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710336312.3A CN107158130B (en) | 2017-05-13 | 2017-05-13 | Chinese patent medicine for treating hypertension |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710336312.3A CN107158130B (en) | 2017-05-13 | 2017-05-13 | Chinese patent medicine for treating hypertension |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN107158130A CN107158130A (en) | 2017-09-15 |
| CN107158130B true CN107158130B (en) | 2020-09-29 |
Family
ID=59815339
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201710336312.3A Expired - Fee Related CN107158130B (en) | 2017-05-13 | 2017-05-13 | Chinese patent medicine for treating hypertension |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN107158130B (en) |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103536690A (en) * | 2013-10-08 | 2014-01-29 | 覃祖仁 | Traditional Chinese medicine oral liquid for reducing blood pressure |
-
2017
- 2017-05-13 CN CN201710336312.3A patent/CN107158130B/en not_active Expired - Fee Related
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103536690A (en) * | 2013-10-08 | 2014-01-29 | 覃祖仁 | Traditional Chinese medicine oral liquid for reducing blood pressure |
Non-Patent Citations (2)
| Title |
|---|
| 尿血、眩晕、不寐;张丽玲;《福建中医药》;19871231(第06期);第46页 * |
| 陈克忠治疗老年高血压病经验;张继东;《江苏中医》;19941231;第15卷(第01期);第6-7页 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN107158130A (en) | 2017-09-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103141709A (en) | Carp feed and preparation method thereof | |
| KR101627837B1 (en) | Health supplement food comprising horse bone extracts as main ingredients and sea horse and manufacturing method for the same | |
| CN115120689A (en) | Application of Xinli rehabilitation formula preparation in preparation of medicines | |
| CN107551001B (en) | A Chinese medicinal composition for preventing and treating alcoholic hepatic injury and its preparation method | |
| CN101884749B (en) | Particle for eliminating turbidity and treating arthralgia | |
| CN108783465A (en) | A kind of nutrition formula product with oncotherapy function | |
| CN107158130B (en) | Chinese patent medicine for treating hypertension | |
| CN110876768A (en) | Traditional Chinese medicine formula, preparation method and application for losing weight, reducing fat and reducing blood fat | |
| CN111375022B (en) | Traditional Chinese medicine composition for treating prostatic hyperplasia | |
| CN108514093B (en) | Multifunctional food composition for assisting in reducing blood sugar and preparation method thereof | |
| CN112870267A (en) | New medicine for treating tumor and preparation method thereof | |
| CN108452240B (en) | Anti-tumor traditional Chinese medicine composition and application thereof | |
| CN102319318B (en) | Chinese medicinal superfine powder preparation for preventing and treating heat toxin and blood dysentery of chicken and preparation method thereof | |
| CN110101813A (en) | It is a kind of to treat kidney-yang deficiency oyster composition oral liquid and preparation method thereof and its application | |
| CN107260981B (en) | Chinese patent medicine for treating constipation | |
| CN100525804C (en) | Chinese traditional medicine compound preparations having a function of slimming | |
| CN103271992B (en) | Pharmaceutical composition for improving immunity | |
| CN112516174B (en) | A product containing internal organs of sea intestine and its preparation method | |
| CN1181840C (en) | Medicine for treating Alzheimer disease and cerebral ischemic encephalopathy and its prepn | |
| RU2259835C2 (en) | Method for preparing anti-inflammatory, wound-healing, capillary-strengthening and immunomodulating agent | |
| CN114366800B (en) | Traditional Chinese medicine for treating colorectal cancer and preparation method thereof | |
| CN1256117C (en) | Medicine for treating chronic ulcerative colitis and its preparation process | |
| CN114306544B (en) | Hypoglycemic composition and preparation method thereof | |
| JP5173432B2 (en) | Herbal formulation for joints | |
| CN106177391A (en) | A kind of pharmaceutical composition treating cancer and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20200929 |